Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections
Copyright policy )Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections
MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that intranasal prophylaxis with MV130 modulates the lung immune landscape and provides long-term heterologous protection against viral respiratory infections in mice. Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. Moreover, pharmacological inhibition of trained immunity with metformin abrogates the protection conferred by MV130 against influenza A virus respiratory infection. MV130 induces reprogramming of both mouse bone marrow progenitor cells and in vitro human monocytes, promoting an enhanced cytokine production that relies on a metabolic shift. Our results unveil that the mucosal administration of a fully inactivated bacterial vaccine provides protection against viral infections by a mechanism associated with the induction of trained immunity.
*polybacterial immunomodulator, Respiratory Mucosa, Antibodies, Viral, Article, Monocytes, *human monocytes, Cell Line, *mucosal, *trained immunity, Mice, L Cells, Orthomyxoviridae Infections, *Candida albicans, Chlorocebus aethiops, Animals, Humans, *influenza, Respiratory Tract Infections, Immunity, Mucosal, Lung, *viral infection, Administration, Intranasal, Mice, Knockout, Bacteria, Candidiasis, Metformin, Mice, Inbred C57BL, Vaccines, Inactivated, Influenza A virus, *macrophages, Bacterial Vaccines, Cytokines, *respiratory infection, *vaccine
*polybacterial immunomodulator, Respiratory Mucosa, Antibodies, Viral, Article, Monocytes, *human monocytes, Cell Line, *mucosal, *trained immunity, Mice, L Cells, Orthomyxoviridae Infections, *Candida albicans, Chlorocebus aethiops, Animals, Humans, *influenza, Respiratory Tract Infections, Immunity, Mucosal, Lung, *viral infection, Administration, Intranasal, Mice, Knockout, Bacteria, Candidiasis, Metformin, Mice, Inbred C57BL, Vaccines, Inactivated, Influenza A virus, *macrophages, Bacterial Vaccines, Cytokines, *respiratory infection, *vaccine
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).69 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!